J. Leone and B. Leone, Breast cancer brain metastases: the last frontier, Experimental Hematology & Oncology, vol.13, issue.6, p.33, 2015.
DOI : 10.1186/bcr3071

URL : https://doi.org/10.1186/s40164-015-0028-8

C. Lu-emerson and A. Eichler, Brain Metastases, CONTINUUM: Lifelong Learning in Neurology, vol.18, pp.295-311, 2012.
DOI : 10.1212/01.CON.0000413659.12304.a6

I. Krop, N. Lin, K. Blackwell, E. Guardino, J. Huober et al., Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA, Annals of Oncology, vol.26, issue.1, pp.113-122, 2015.
DOI : 10.1093/annonc/mdu486

E. Lim and N. Lin, Updates on the management of breast cancer brain metastases, Oncology, vol.28, pp.572-580, 2014.

A. Niwinska, M. Murawska, and K. Pogoda, Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT), Annals of Oncology, vol.21, issue.5, pp.942-950, 2010.
DOI : 10.1093/annonc/mdp407

URL : https://academic.oup.com/annonc/article-pdf/21/5/942/644009/mdp407.pdf

S. Swain, J. Baselga, S. Kim, J. Ro, V. Semiglazov et al., Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer, New England Journal of Medicine, vol.372, issue.8, pp.724-758, 2015.
DOI : 10.1056/NEJMoa1413513

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584549/pdf

S. Swain, J. Baselga, D. Miles, Y. Im, C. Quah et al., Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA, Annals of Oncology, vol.25, issue.6, pp.1116-1137, 2014.
DOI : 10.1093/annonc/mdu133

M. Gill, N. Falzone, Y. Du, and K. Vallis, Targeted radionuclide therapy in combined-modality regimens, The Lancet Oncology, vol.18, issue.7, pp.414-437, 2017.
DOI : 10.1016/S1470-2045(17)30379-0

J. Pouget, I. Navarro-teulon, M. Bardies, N. Chouin, G. Cartron et al., Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-754, 2011.
DOI : 10.1158/1078-0432.CCR-1004-0023

S. Enger, T. Hartman, J. Carlsson, and H. Lundqvist, Cross-fire doses from ??-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics, Physics in Medicine and Biology, vol.53, issue.7, pp.1909-1929, 2008.
DOI : 10.1088/0031-9155/53/7/007

P. Erba, M. Sollini, E. Orciuolo, C. Traino, M. Petrini et al., Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies, Journal of Nuclear Medicine, vol.53, issue.6, pp.922-929, 2012.
DOI : 10.2967/jnumed.111.101006

S. Sauer, P. Erba, M. Petrini, A. Menrad, L. Giovannoni et al., Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients, Blood, vol.113, issue.10, pp.2265-74, 2009.
DOI : 10.1182/blood-2008-06-160416

G. Poli, C. Bianchi, G. Virotta, A. Bettini, R. Moretti et al., Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study, Cancer Immunology Research, vol.1, issue.2, pp.134-177, 2013.
DOI : 10.1158/2326-6066.CIR-13-0007

S. Kneifel, D. Cordier, S. Good, M. Ionescu, A. Ghaffari et al., Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P, Clinical Cancer Research, vol.12, issue.12, pp.3843-50, 2006.
DOI : 10.1158/1078-0432.CCR-05-2820

D. Cordier, F. Forrer, F. Bruchertseifer, A. Morgenstern, C. Apostolidis et al., Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial, European Journal of Nuclear Medicine and Molecular Imaging, vol.19, issue.4, pp.1335-1379, 2010.
DOI : 10.4161/cbt.4.12.2251

D. Reardon, G. Akabani, R. Coleman, A. Friedman, H. Friedman et al., Salvage Radioimmunotherapy With Murine Iodine-131???Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results, Journal of Clinical Oncology, vol.24, issue.1, pp.115-137, 2006.
DOI : 10.1200/JCO.2005.03.4082

D. Reardon, M. Zalutsky, G. Akabani, R. Coleman, A. Friedman et al., A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost, Neuro-Oncology, vol.10, issue.2, pp.182-191, 2008.
DOI : 10.1215/15228517-2007-053

URL : https://academic.oup.com/neuro-oncology/article-pdf/10/2/182/13064864/NO102_10_Reardon.pdf

M. Zalutsky, D. Reardon, G. Akabani, R. Coleman, A. Friedman et al., Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008.
DOI : 10.2967/jnumed.107.046938

M. Soto, S. Serres, D. Anthony, and N. Sibson, Functional role of endothelial adhesion molecules in the early stages of brain metastasis, Neuro-Oncology, vol.16, issue.4, pp.540-51, 2014.
DOI : 10.1093/neuonc/not222

S. Serres, S. Mardiguian, S. Campbell, M. Mcateer, A. Akhtar et al., VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis, The FASEB Journal, vol.25, issue.12, pp.4415-4437, 2011.
DOI : 10.1096/fj.11-183772

J. Scalici, S. Thomas, C. Harrer, T. Raines, J. Curran et al., Imaging VCAM-1 as an Indicator of Treatment Efficacy in Metastatic Ovarian Cancer, Journal of Nuclear Medicine, vol.54, issue.11, pp.1883-1892, 2013.
DOI : 10.2967/jnumed.112.117796

E. Hindie, P. Zanotti-fregonara, M. Quinto, C. Morgat, and C. Champion, Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy, Journal of Nuclear Medicine, vol.57, issue.5, pp.759-64, 2016.
DOI : 10.2967/jnumed.115.170423

C. Champion, M. Quinto, C. Morgat, P. Zanotti-fregonara, and E. Hindie, Tb, with Emphasis on Doses Delivered to Minimal Residual Disease, Theranostics, vol.6, issue.10, pp.1611-1619, 2016.
DOI : 10.7150/thno.15132

URL : http://www.thno.org/v06p1611.pdf

M. Bernal and J. Liendo, An investigation on the capabilities of the PENELOPE MC code in nanodosimetry, Medical Physics, vol.68, issue.1, pp.620-625, 2009.
DOI : 10.1103/PhysRevA.68.012708

M. Bernal, D. Sikansi, F. Cavalcante, S. Incerti, C. Champion et al., An atomistic geometrical model of the B-DNA configuration for DNA???radiation interaction simulations, Computer Physics Communications, vol.184, issue.12, pp.2840-2847, 2013.
DOI : 10.1016/j.cpc.2013.07.015

URL : https://hal.archives-ouvertes.fr/in2p3-00918490

T. Yoneda, P. Williams, T. Hiraga, M. Niewolna, and R. Nishimura, A Bone-Seeking Clone Exhibits Different Biological Properties from the MDA-MB-231 Parental Human Breast Cancer Cells and a Brain-Seeking Clone In Vivo and In Vitro, Journal of Bone and Mineral Research, vol.10, issue.8, pp.1486-95, 2001.
DOI : 10.1038/bjc.1997.513

J. Larkin, A. Dickens, T. Claridge, C. Bristow, K. Andreou et al., Early Diagnosis of Brain Metastases Using a Biofluids-Metabolomics Approach in Mice, Theranostics, vol.6, issue.12, pp.2161-2170, 2016.
DOI : 10.7150/thno.16538

A. Shih, C. Mateo, P. Drew, P. Tsai, and D. Kleinfeld, A Polished and Reinforced Thinned-skull Window for Long-term Imaging of the Mouse Brain, Journal of Visualized Experiments, vol.61, issue.61, pp.3791-3833, 2012.
DOI : 10.3791/3742

S. Agostinelli, J. Allison, K. Amako, J. Apostolakis, H. Araujo et al., Geant4???a simulation toolkit, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, vol.506, issue.3, pp.250-303, 2003.
DOI : 10.1016/S0168-9002(03)01368-8

URL : https://hal.archives-ouvertes.fr/in2p3-00020246

I. Incerti, G. Baldacchino, M. Bernal, R. Capra, C. Champion et al., THE GEANT4-DNA PROJECT, International Journal of Modeling, Simulation, and Scientific Computing, vol.01, issue.02, pp.157-78, 2010.
DOI : 10.1118/1.3056457

URL : https://hal.archives-ouvertes.fr/in2p3-00468402

W. Friedland, P. Jacob, H. Paretzke, M. Merzagora, and A. Ottolenghi, Simulation of DNA fragment distributions after irradiation with photons, Radiation and Environmental Biophysics, vol.38, issue.1, pp.39-47, 1999.
DOI : 10.1007/s004110050136

W. Friedland, P. Jacob, P. Bernhardt, H. Paretzke, and M. Dingfelder, Simulation of DNA Damage after Proton Irradiation, Radiation Research, vol.159, issue.3, pp.401-411, 2003.
DOI : 10.1667/0033-7587(2003)159[0401:SODDAP]2.0.CO;2

F. Natale, A. Rapp, W. Yu, A. Maiser, H. Harz et al., Identification of the elementary structural units of the DNA damage response, Nature Communications, vol.5, p.15760, 2017.
DOI : 10.1038/nmeth.1226

R. Meredith, J. Torgue, S. Shen, D. Fisher, E. Banaga et al., Dose Escalation and Dosimetry of First-in-Human ?? Radioimmunotherapy with 212Pb-TCMC-Trastuzumab, Journal of Nuclear Medicine, vol.55, issue.10, pp.1636-1678, 2014.
DOI : 10.2967/jnumed.114.143842

S. Serres, M. Soto, A. Hamilton, M. Mcateer, W. Carbonell et al., Molecular MRI enables early and sensitive detection of brain metastases, Proceedings of the National Academy of Sciences, vol.16, issue.8, pp.6674-6683, 2012.
DOI : 10.1359/jbmr.2001.16.8.1486

A. Berghoff, O. Rajky, F. Winkler, R. Bartsch, J. Furtner et al., Invasion patterns in brain metastases of solid cancers, Neuro-Oncology, vol.15, issue.12, pp.1664-72, 2013.
DOI : 10.1093/neuonc/not112

T. Jochimsen, D. Ivanov, D. Ott, W. Heinke, R. Turner et al., Whole-brain mapping of venous vessel size in humans using the hypercapnia-induced BOLD effect, NeuroImage, vol.51, issue.2, pp.765-74, 2010.
DOI : 10.1016/j.neuroimage.2010.02.037

J. Elgqvist, S. Frost, J. Pouget, and P. Albertsson, The Potential and Hurdles of Targeted Alpha Therapy ??? Clinical Trials and Beyond, Frontiers in Oncology, vol.3, p.324, 2014.
DOI : 10.3389/fonc.2013.00324

M. Bernal, Evaluation of the mean energy deposit during the impact of charged particles on liquid water, Physics in Medicine and Biology, vol.57, issue.7, pp.1745-57, 2012.
DOI : 10.1088/0031-9155/57/7/1745

M. Bernal, C. Dealmeida, C. Sampaio, S. Incerti, C. Champion et al., The invariance of the total direct DNA strand break yield, Medical Physics, vol.262, issue.1, pp.4147-53, 2011.
DOI : 10.1016/j.nimb.2007.05.001

URL : https://hal.archives-ouvertes.fr/in2p3-00621281

T. Nayak, J. Norenberg, T. Anderson, E. Prossnitz, M. Stabin et al., Somatostatin-receptor-targeted ??-emitting 213Bi is therapeutically more effective than ?????-emitting 177Lu in human pancreatic adenocarcinoma cells, Nuclear Medicine and Biology, vol.34, issue.2, pp.185-93, 2007.
DOI : 10.1016/j.nucmedbio.2006.11.006

T. Friedrich, U. Scholz, T. Elsasser, D. M. Scholz, and M. , Systematic analysis of RBE and related quantities using a database of cell survival experiments with ion beam irradiation, Journal of Radiation Research, vol.54, issue.3, pp.494-514, 2013.
DOI : 10.1093/jrr/rrs114

F. Graf, J. Fahrer, S. Maus, A. Morgenstern, F. Bruchertseifer et al., DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy, PLoS ONE, vol.120, issue.2, p.88239, 2014.
DOI : 10.1371/journal.pone.0088239.t001

D. Mulford, D. Scheinberg, and J. Jurcic, The promise of targeted ?-particle therapy, J Nucl Med, vol.46, pp.199-204, 2005.

R. Meredith, J. Torgue, M. Azure, S. Shen, S. Saddekni et al., Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients, Cancer Biotherapy & Radiopharmaceuticals, vol.29, issue.1, pp.12-19, 2014.
DOI : 10.1089/cbr.2013.1531

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869429/pdf

K. Baidoo, D. Milenic, and M. Brechbiel, Methodology for labeling proteins and peptides with lead-212 (212Pb), Nuclear Medicine and Biology, vol.40, issue.5, pp.592-601, 2013.
DOI : 10.1016/j.nucmedbio.2013.01.010

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665721/pdf

R. Meredith, J. Torgue, T. Rozgaja, E. Banaga, P. Bunch et al., Safety and outcome measures of first-in-human intraperitoneal alpha radioimmunotherapy with 212 Pb-TCMC-Trastuzumab, Am J Clin Oncol, 2016.

K. Yong and M. Brechbiel, Towards translation of (212)Pb as a clinical therapeutic; Getting the lead in! Dalton Trans, pp.6068-76, 2011.

T. Siegal, Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol, pp.656-69, 2013.
DOI : 10.1093/neuonc/not016

URL : https://academic.oup.com/neuro-oncology/article-pdf/15/6/656/12820767/not016.pdf

J. Connell, G. Chatain, B. Cornelissen, K. Vallis, A. Hamilton et al., Selective Permeabilization of the Blood???Brain Barrier at Sites of Metastasis, JNCI: Journal of the National Cancer Institute, vol.105, issue.21, pp.1634-1677, 2013.
DOI : 10.1093/jnci/djt276

H. Thisgaard, B. Halle, C. Aaberg-jessen, B. Olsen, A. Therkelsen et al., Highly Effective Auger-Electron Therapy in an Orthotopic Glioblastoma Xenograft Model using Convection-Enhanced Delivery, Theranostics, vol.6, issue.12, pp.2278-91, 2016.
DOI : 10.7150/thno.15898

URL : http://www.thno.org/v06p2278.pdf